HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62

Benzinga · 3d ago
HC Wainwright & Co. analyst Douglas Tsao maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $55 to $62.